Based on a foundation of over 15 years of research, Devonian’s focus is further supported by a US-FDA set of regulatory guidelines favouring a more efficient drug development pathway for prescription ...
Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage botanical pharmaceutical corporation focused on ...
QUEBEC CITY--(BUSINESS WIRE)--Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD; OTCQB: DVHGF), a clinical stage botanical pharmaceutical corporation, focused on developing a ...
Devonian Health Group Announces the Formation of a Scientific Advisory Board with Mandate to Assist in the Development of Cannabinoïds-Based Pharmaceutical Products. Devonian Health Group Inc.
"Our year-end results reflect a company that is financially disciplined, debt-free, and strategically positioned for the next phase of value creation. With this strong foundation, we are intensifying ...
QUEBEC CITY — Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a clinical stage botanical pharmaceutical corporation focused on developing a unique portfolio of botanical ...
The Company announces that the Board of Directors has approved the granting of 2,948,056 stock options to directors and a consultant of the Company. Of the options, 2,798,056 were granted to directors ...
Luc Grégoire, current Director of Devonian, appointed as President and CEO, brings 30 years of financial capital markets, strategic and operational leadership David Baker transitions from board ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results